Target intelligence / Profile preview

HLA class II histocompatibility antigen, DRB1-4 beta chain (HLA-DRB1*04:01) (HLA-DRB1*04:01)

Target
HLA-DRB1*04:01
Molecular classification
MHC class II molecule, Receptor, Antigen-presenting protein
01

Overview

HLA-DRB1*04:01 is a specific allele of the human leukocyte antigen (HLA) class II beta chain, which forms a heterodimer with the HLA-DRA chain to create the HLA-DR receptor (UniProt P01911). This molecule is primarily expressed on the surface of professional antigen-presenting cells, such as dendritic cells and B cells. Its primary biological function is the presentation of exogenous peptides to CD4+ T-helper cells, a critical step in the initiation of the adaptive immune response. The peptide-binding groove of the HLA-DRB1*04:01 allele is characterized by a specific sequence known as the "shared epitope," which is highly associated with an increased risk and severity of rheumatoid arthritis (Gregersen et al., 1987). In autoimmune contexts, this groove binds and presents self-antigens, such as citrullinated proteins, leading to the loss of self-tolerance and chronic inflammation (Scally et al., 2013). Therapeutic strategies targeting this groove aim to block the presentation of these pathogenic peptides or induce immune tolerance through the use of altered peptide ligands or small molecule inhibitors (Benham et al., 2015).

Other names
MHC class II antigen DRB1*0401DR4Shared Epitope-positive HLA-DRB1HLA-DRB1*04:01 peptide-binding groove
02

Mechanism of action

Competitive inhibition of the peptide-binding groove to prevent the presentation of arthritogenic self-antigens to CD4+ T cells, thereby reducing autoimmune activation.

03

Biological functions

Antigen presentationImmune responseT-cell activation
04

Disease associations

Rheumatoid arthritisType 1 diabetesAutoimmune disease
05

Safety considerations

Potential for broad immunosuppressionRisk of opportunistic infectionsInterference with normal antigen presentation
06

Interacting drugs

Rheumavax (experimental)

3 more in the full profile.

07

Biomarkers

HLA-DRB1*04:01 genotypeAnti-citrullinated protein antibodies (ACPA)

Beyond the preview

Go deeper on HLA class II histocompatibility antigen, DRB1-4 beta chain (HLA-DRB1*04:01) (HLA-DRB1*04:01).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class II histocompatibility antigen, DRB1-4 beta chain (HLA-DRB1*04:01) (HLA-DRB1*04:01).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call